The Comparative Effects of Monotherapy with Topical Minoxidil, Oral Finasteride, and Topical Finasteride in Postmenopausal Women with Pattern Hair Loss: A Retrospective Cohort Study.
Alopecia
Androgenetic alopecia
Female alopecia
Journal
Skin appendage disorders
ISSN: 2296-9195
Titre abrégé: Skin Appendage Disord
Pays: Switzerland
ID NLM: 101670617
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
received:
08
01
2024
accepted:
27
03
2024
pmc-release:
01
08
2025
medline:
7
8
2024
pubmed:
7
8
2024
entrez:
7
8
2024
Statut:
ppublish
Résumé
Oral finasteride and topical minoxidil are long-standing androgenetic alopecia (AGA) treatments; topical finasteride is a more recent medicine. Few studies have compared their therapeutic effects in postmenopausal women. We compared the therapeutic impact of topical finasteride (1-4 sprays of 0.25% topical finasteride solution daily for 12 months), oral finasteride (2.5 mg oral finasteride once daily for 12 months), and topical minoxidil (1 mL of topical minoxidil 5% twice daily for 12 months) in postmenopausal women with AGA. We conducted Bayesian network meta-analyses of individual patient-level data insofar as four clinically relevant endpoints, namely, 12-month change in (1) total hair density, (2) hair diameter, (3) clinical photographs, and (4) patients' opinion of efficacy. Data were obtained through medical charts. Regimens' surface under the cumulative ranking distribution (SUCRA) values and relative effects - as per odds ratios - were computed. As per SUCRA, the most and least effective regimens - across the four outcomes - were oral finasteride, and topical finasteride, respectively; however, no significant statistical differences were found (i.e., Oral finasteride is ranked more effective than the topical forms of minoxidil and finasteride; however, more studies are needed to confirm this result.
Identifiants
pubmed: 39108554
doi: 10.1159/000538621
pii: 538621
pmc: PMC11299975
doi:
Types de publication
Journal Article
Langues
eng
Pagination
293-300Informations de copyright
© 2024 S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.